# US 2024/0254233 A1 · Bispecific antibody specifically binding to cd47 and pd-l1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254233 A1
- Document ID: US20240254233A1
- Status: Published application
- Kind: A1
- Application number: 18/289,696
- Filed: 2022-05-06
- Published: 2024-08-01
- Earliest claimed: 2021-05-07
- Assignees: Immuneoncia Therapeutics, Inc.
- Applicants: Immuneoncia Therapeutics, Inc.
- Inventors: Jeong Kook KIM; A-Ra JEON; Hyeon Seok YOO; Jihyun PARK; Ji Eun PARK; Ji-Hye CHOI; Heewook SHIN; Jiyea CHOI; Sun Kwang SONG; Heung Tae KIM; Sung Ho KIM
- Web page: https://patentgrep.com/patent/US20240254233A1

## CPC

- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/74: Inducing cell proliferation
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A bispecific antibody is disclosed. The bispecific antibody has a high binding affinity to tumor cells expressing PD-L1 and/or CD47. The bispecific antibody exhibits an excellent antitumoral effect with minimal side effects of hemagglutination. A polynucleotide encoding the bispecific antibody, a vector containing the polynucleotide, and a host cell containing the vectore are also disclosed.

## Claims

### Claim 1

A bispecific antibody, comprising a first antigen binding domain that specifically binds to CD47, and a second antigen binding domain that specifically binds to PD-L1,
wherein the first antigen binding domain comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising CDR1 that comprises the amino acid sequence of SEQ ID NO: 17, CDR2 that comprises the amino acid sequence of SEQ ID NO: 19, and CDR3 that comprises the amino acid sequence of SEQ ID NO: 21, and the light chain variable region comprising CDR1 that comprises the amino acid sequence of SEQ ID NO: 23, CDR2 that comprises the amino acid sequence of SEQ ID NO: 25, and CDR3 that comprises the amino acid sequence of SEQ ID NO: 27, and
the second antigen binding domain comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising CDR1 that comprises the amino acid sequence of SEQ ID NO: 29, CDR2 that comprises the amino acid sequence of SEQ ID NO: 31, and CDR3 that comprises the amino acid sequence of SEQ ID NO: 33, and the light chain variable region comprising CDR1 that comprises the amino acid sequence of SEQ ID NO: 35, CDR2 that comprises the amino acid sequence of SEQ ID NO: 37, and CDR3 that comprises the amino acid sequence of SEQ ID NO: 39.

### Claim 2 (depends on 1)

The bispecific antibody of claim 1, wherein the first antigen binding domain comprises a heavy chain variable region of SEQ ID NO: 1 and a light chain variable region of SEQ ID NO: 3.

### Claim 3 (depends on 1)

The bispecific antibody of claim 1, wherein the second antigen binding domain comprises (i) a heavy chain variable region of SEQ ID NO: 5 and a light chain variable region of SEQ ID NO: 7 or (ii) a single chain variable fragment (scFv) of SEQ ID NO: 9.

### Claim 4 (depends on 1)

The bispecific antibody of claim 1, wherein the bispecific antibody comprises an Fc domain, a first antibody fragment comprising the antigen binding domain that specifically binds to CD47, and a second antibody fragment comprising the antigen binding domain that specifically binds to PD-L1.

### Claim 5 (depends on 4)

The bispecific antibody of claim 4, wherein the first antibody fragment is an Fab fragment, and the second antibody fragment is a single chain variable fragment (scFv).

### Claim 6 (depends on 4)

The bispecific antibody of claim 4, wherein the second antibody fragment is fused, via a peptide linker, to the C-terminus of the Fc domain.

### Claim 7 (depends on 1)

The bispecific antibody of claim 1, wherein the bispecific antibody comprises an Fc domain, two Fab fragments each comprising the antigen binding domain that specifically binds to CD47, and two scFv fragments each comprising the antigen binding domain that specifically binds to PD-L1.

### Claim 8 (depends on 1)

The bispecific antibody of claim 1, wherein the bispecific antibody comprises a single chain variable fragment (scFv) comprising the antigen binding domain that specifically binds to PD-L1.

### Claim 9 (depends on 1)

The bispecific antibody of claim 1, wherein the bispecific antibody comprises an Fab fragment comprising the antigen binding domain that specifically binds to CD47.

### Claim 10 (depends on 1)

The bispecific antibody of claim 1, wherein the bispecific antibody comprises an Fc region derived from the heavy chain constant region (CH) of IgG1.

### Claim 11 (depends on 10)

The bispecific antibody of claim 10, wherein the Fc region comprises heavy chain constant regions CH1, CH2, and CH3 derived from IgG1, and CH3 contains amino acid substitutions of E239D and M241L with respect to SEQ ID NO: 11.

### Claim 12 (depends on 10)

The bispecific antibody of claim 10, wherein the Fc region acts on effector cells to exhibit an immune activation effect.

### Claim 13 (depends on 10)

The bispecific antibody of claim 10, wherein the bispecific antibody comprises an antibody fragment comprising the antigen binding domain that specifically binds to PD-L1, and the antibody fragment is fused to the C-terminus of the Fc domain via a peptide linker.

### Claim 14 (depends on 8)

The bispecific antibody of claim 8, wherein the single chain variable fragment (scFV) comprises the amino acid sequence of SEQ ID NO: 9.

### Claim 15 (depends on 10)

The bispecific antibody of claim 10, wherein the Fc region comprises the amino acid sequence of SEQ ID NO: 11.

### Claim 16 (depends on 1)

The bispecific antibody of claim 1, wherein the bispecific antibody specifically binds cancer cells that express PD-L1, CD47, or both.

### Claim 17 (depends on 1)

The bispecific antibody of claim 1, for use in prevention or treatment of a carcinoma selected from the group consisting of breast cancer, lung cancer, B cell-derived lymphoma, and T cell-derived lymphoma.

### Claim 18 (depends on 1)

A pharmaceutical composition for prevention or treatment of cancer, comprising:
the bispecific antibody of claim 1.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein the cancer is selected from the group consisting of ovarian cancer, colon cancer, breast cancer, lung cancer, myeloma, neuroblast-derived CNS tumor, monocytic leukemia, B cell-derived leukemia, T cell-derived leukemia, B cell-derived lymphoma, T cell-derived lymphoma, and mast cell-derived tumor.

### Claim 20 (depends on 18)

The pharmaceutical composition of claim 18, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, B cell-derived lymphoma, and T cell-derived lymphoma.

### Claim 21 (depends on 1)

A pharmaceutical composition for use in inhibition of tumor cell growth, comprising:
the bispecific antibody of claim 1.

### Claim 22 (depends on 18)

The pharmaceutical composition of claim 18, wherein the bispecific antibody is used or administered in combination with chemotherapy, radiation therapy, and/or another cancer immunotherapeutic agent.

### Claim 23 (depends on 1)

A use of the bispecific antibody of claim 1, for prevention or treatment of various carcinomas including breast cancer, lung cancer, B cell-derived lymphoma, and T cell-derived lymphoma.

### Claim 24 (depends on 1)

A method for preventing or treating cancer, comprising:
administering an effective amount of the bispecific antibody of claim 1 to a subject in need of prevention or treatment of cancer.

### Claim 25 (depends on 1)

A method for inhibiting growth of tumor cells in a subject, comprising:
administering, to the subject having tumor cells, an effective amount of the bispecific antibody of claim 1.

### Claim 26 (depends on 1)

A polynucleotide, encoding the bispecific antibody of claim 1.

### Claim 27 (depends on 26)

A host cell, comprising the polynucleotide of claim 26.

### Claim 28 (depends on 1)

A method for preparing the bispecific antibody of claim 1, comprising:
culturing a host cell comprising a polynucletodie encoding the bispecific antibody of claim 1 under a condition suitable for expression of the bispecific antibody; and
collecting the bispecific antibody from the culture.
